MarketPulse

VYKAT™ XR

4 articles
The Motley FoolThe Motley Fool··Eric Volkman

Neurocrine Snaps Up Soleno for $2.9B, Betting Big on Rare Disease Drug

Neurocrine Biosciences to acquire Soleno Therapeutics for $2.9B in all-cash deal, paying $53/share—a 34% premium driven by Soleno's FDA-approved Vykat XR for Prader-Willi Syndrome.
SLNONBIXacquisitionFDA approval
BenzingaBenzinga··Vandana Singh

Neurocrine Acquires Soleno for $2.9B to Dominate Rare Disease Market

Neurocrine acquires Soleno for $2.9B to gain Vykat XR, a rare disease blockbuster generating $190M in 2025 revenue.
SLNONBIXacquisitionFDA approval
GlobeNewswire Inc.GlobeNewswire Inc.··Hagens Berman

Soleno's VYKAT XR Faces Legal Storm as Safety Concerns Tank Stock 40%

Soleno Therapeutics faces securities lawsuit after hyperphagia drug VYKAT XR launch falters amid safety concerns, driving shares down 40% since August short seller report.
SLNOstock declinesecurities class action
GlobeNewswire Inc.GlobeNewswire Inc.··Hagens Berman

Soleno Therapeutics Hit With Class Action Over VYKAT Launch Failures and Safety Disclosures

$SLNO faces securities lawsuit alleging misleading safety claims for hyperphagia drug VYKAT XR. Stock crashed 40% after short seller report and management admissions of launch disruptions.
SLNOsecurities class actionclinical trial